Arrowhead Pharmaceuticals Q4 2024 Earnings Report

Arrowhead Pharmaceuticals announced its 2024 fiscal year-end results, reporting a net loss attributable to Arrowhead Pharmaceuticals, Inc. of $599.493 million and revenue of $3.551 million.

Key Takeaways

Arrowhead Pharmaceuticals reported its fiscal year-end results, highlighted by the submission of an NDA for plozasiran and a significant licensing and collaboration agreement with Sarepta Therapeutics. These strategic moves aim to strengthen the company's balance sheet and advance its pipeline.

Submitted NDA to the U.S. FDA for investigational plozasiran.

Entered into a licensing and collaboration agreement with Sarepta Therapeutics for $825 million upfront.

Closed a strategic financing agreement with Sixth Street for a $500 million senior secured credit facility.

Plozasiran received Breakthrough Therapy designation from the FDA.

Total Revenue

$3.55M

Previous year: $16.1M

-77.9%

EPS

-$1.37

Previous year: -$1.02

+34.3%